Ono Pharmaceutical Co., Ltd.
Clinical trials sponsored by Ono Pharmaceutical Co., Ltd., explained in plain language.
Japanese pharmaceutical company focused on oncology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to soothe agitation in Alzheimer's patients Results expected Dec 2026 (estimated)
- New hope for tough lymphoma: experimental drug ONO-4685 enters human testing Results expected Aug 2027 (estimated)
-
Can a MALT1 blocker tame Hard-to-Treat lymphoma?
Disease control Stopped earlyThis early-stage trial is testing an experimental drug called ONO-7018 in people with relapsed or refractory Non-Hodgkin lymphoma. The drug works by blocking a protein called MALT1 that may help lymphoma cells grow. The study aims to see if the drug is safe and tolerable, and how…
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for tough blood cancers: early trial of ONO-7018 begins
Disease control Stopped earlyThis early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped earl…
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC